Supriya Lifescience Ltd., a cGMP-compliant API manufacturer with a presence in over 86 countries, has announced its unaudited financial results for the first quarter of FY26. The company operates across multiple therapeutic categories, including anti-histamine, anti-allergic, vitamins, anaesthetics, and anti-asthmatics.

In Q1 FY26, the company reported a year-on-year decline in revenue, primarily due to delays in production at its Lote facility. This was caused by essential repair and maintenance work aimed at improving efficiency in older manufacturing blocks and preparing Module E for new product launches. Despite the dip in topline numbers, profitability metrics remained resilient, with strong EBITDA margins supported by better backward integration and a rising contribution from regulated markets.

The anaesthetic segment emerged as the top revenue contributor during the quarter, accounting for more than half of total sales, up significantly from the same period last year. The company also saw notable growth in its European business, which now represents a larger share of overall revenue. Capacity utilisation improved compared to the previous fiscal, reflecting operational recovery.

To support future growth, Supriya Lifescience has acquired three separate land parcels near different plants. These will be used to expand manufacturing capacity and strengthen its supply capabilities for upcoming product launches.

Commenting on the results, Chairman and Managing Director Satish Wagh said the quarter’s performance reflected a temporary setback from the facility upgrade work. He emphasised that these investments were crucial for sustaining long-term operational efficiency and enabling full utilisation of production assets.

“Despite the revenue dip, EBITDA margins remained strong, backed by improved backward integration and increased contribution from regulated markets. With the Ambernath site on track for commercial production in Q4, a strong pipeline of 3–4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach ₹1,000 crore revenue by FY27,” Wagh said.

The company remains confident that its diversified therapeutic portfolio, ongoing capacity expansions, and robust international presence will help it achieve its medium-term growth targets, even as it navigates short-term operational disruptions.